Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

7.290 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

September 01, 2022

From Kezar Life Science

Via Business Wire

Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 11, 2022

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 03, 2022

From Kezar Life Sciences, Inc.

Via Business Wire

Wells Fargo Beefs Up Kezar Life Price Target - Read Why ↗

June 28, 2022

Via Benzinga

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

July 11, 2022

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating ↗

July 08, 2022

The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81.

Via Investor's Business Daily

Kezar Life Sciences to Present at the William Blair Biotech Focus Conference

July 07, 2022

From Kezar Life Sciences, Inc.

Via Business Wire

Kezar Life Sciences (KZR) Stock Soars on Lupus Trial Results ↗

June 28, 2022

KZR stock is soaring today on news that Kezar Life Sciences' Lupus treatment showed positive results in a clinical trial.

Via InvestorPlace

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 06, 2022

From Kezar Life Sciences, Inc.

Via Business Wire

The Week In Charts: How To Make Money While Waiting For Core Trend Trades ↗

July 02, 2022

The real money is in the longer-term core trend trades. However, sometimes those opportunities can be few and far between. This is especially true in a bear market.

Via Talk Markets

Biotech ETF Tops in June: 5 Stocks That Outperform ↗

June 30, 2022

Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%.

Via Talk Markets

Short Volatility Alert: Kezar Life Sciences, Inc. ↗

June 29, 2022

On Tuesday, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) experienced volatile short activity. After the activity, the stock price went up +43.43% to $8.29. The overall sentiment for KZR has been...

Via Benzinga

InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday ↗

June 29, 2022

Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Dow Dips Over 400 Points; Crude Oil Rises 2% ↗

June 28, 2022

U.S. stocks turned sharply lower toward the end of trading, with the Dow Jones dropping more than 400 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 28, 2022

Gainers

Via Benzinga

Nasdaq Turns Lower; Kezar Life Sciences Shares Jump ↗

June 28, 2022

U.S. stocks pared gains midway through trading, with the Nasdaq Composite and S&P 500 turning lower on Tuesday.

Via Benzinga

Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session ↗

June 28, 2022

Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Occidental Petroleum (OXY) Stock Gets Boost From Yet Another Buffett Buy ↗

June 28, 2022

Occidental Petroleum (OXY) stock is rising on Tuesday after Warren Buffett's Berkshire Hathaway increased its stake in the company.

Via InvestorPlace

Markets Open Higher; US Goods Gap Narrows To $104.3B In May ↗

June 28, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining over 350 points on Tuesday.

Via Benzinga

Why Kezar Life Sciences Stock Is Soaring Today ↗

June 28, 2022

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging Tuesday after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.

Via Benzinga

The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives ↗

June 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 28, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

June 28, 2022

Good morning! It's time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning!

Via InvestorPlace

Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session ↗

June 28, 2022

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 27, 2022

Gainers

Via Benzinga

Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate ↗

June 27, 2022

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

Via Benzinga

After-Hours Action: Why Kezar Life Sciences Stock Is Soaring ↗

June 27, 2022

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.

Via Benzinga

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

June 27, 2022

From Kezar Life Sciences, Inc.

Via Business Wire

Billionaire Israel Englander Is Betting Big on These 5 Stocks ↗

June 24, 2022

Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month.

Via InvestorPlace

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 03, 2022

From Kezar Life Sciences, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.